624 related articles for article (PubMed ID: 30134964)
1. Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial.
Wang Y; Kuang Y; Chen Q; Cai R
Trials; 2018 Aug; 19(1):455. PubMed ID: 30134964
[TBL] [Abstract][Full Text] [Related]
2. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist.
Lu X; Hong Q; Sun L; Chen Q; Fu Y; Ai A; Lyu Q; Kuang Y
Fertil Steril; 2016 Nov; 106(6):1356-1362. PubMed ID: 27490046
[TBL] [Abstract][Full Text] [Related]
3. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles.
Yu S; Long H; Chang HY; Liu Y; Gao H; Zhu J; Quan X; Lyu Q; Kuang Y; Ai A
Hum Reprod; 2018 Feb; 33(2):229-237. PubMed ID: 29300975
[TBL] [Abstract][Full Text] [Related]
4. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a "freeze all" strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg.
Zhu X; Ye H; Fu Y
Fertil Steril; 2017 Feb; 107(2):379-386.e4. PubMed ID: 27865446
[TBL] [Abstract][Full Text] [Related]
5. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection.
Qin N; Chen Q; Hong Q; Cai R; Gao H; Wang Y; Sun L; Zhang S; Guo H; Fu Y; Ai A; Tian H; Lyu Q; Daya S; Kuang Y
Fertil Steril; 2016 Aug; 106(2):334-341.e1. PubMed ID: 27114329
[TBL] [Abstract][Full Text] [Related]
6. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial.
Dong J; Wang Y; Chai WR; Hong QQ; Wang NL; Sun LH; Long H; Wang L; Tian H; Lyu QF; Lu XF; Chen QJ; Kuang YP
BJOG; 2017 Jun; 124(7):1048-1055. PubMed ID: 28276192
[TBL] [Abstract][Full Text] [Related]
7. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
Xiao ZN; Peng JL; Yang J; Xu WM
Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
[TBL] [Abstract][Full Text] [Related]
8. Progestin-primed ovarian stimulation versus GnRH antagonist protocol in poor responders: Risk of premature LH surge and outcome of oocyte retrieval.
Kao TC; Hsieh YC; Yang IJ; Wu MY; Chen MJ; Yang JH; Chen SU
J Formos Med Assoc; 2023 Jan; 122(1):29-35. PubMed ID: 36123235
[TBL] [Abstract][Full Text] [Related]
9. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial.
Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L
Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207
[TBL] [Abstract][Full Text] [Related]
10. Ovarian response and embryo ploidy following oral micronized progesterone-primed ovarian stimulation versus GnRH antagonist protocol. A prospective study with repeated ovarian stimulation cycles.
Vidal MDM; Martínez F; Rodríguez I; Polyzos NP
Hum Reprod; 2024 May; 39(5):1098-1104. PubMed ID: 38498835
[TBL] [Abstract][Full Text] [Related]
11. Progestin vs. Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surges in Poor Responders Undergoing
Chen Q; Chai W; Wang Y; Cai R; Zhang S; Lu X; Zeng X; Sun L; Kuang Y
Front Endocrinol (Lausanne); 2019; 10():796. PubMed ID: 31824419
[No Abstract] [Full Text] [Related]
12. Progestin-primed ovarian stimulation is a feasible method for poor ovarian responders undergoing in IVF/ICSI compared to a GnRH antagonist protocol: A retrospective study.
Huang P; Tang M; Qin A
J Gynecol Obstet Hum Reprod; 2019 Feb; 48(2):99-102. PubMed ID: 30321608
[TBL] [Abstract][Full Text] [Related]
13. Comparison of a progestin-primed ovarian stimulation protocol with a flexible GnRH antagonist protocol in patients with polycystic ovary syndrome who are participating in an IVF programme: study protocol for a randomised controlled trial.
Wang N; Zhu Q; Ma M; Liang Z; Tao Y; Wang Y; Kuang Y
BMJ Open; 2020 Dec; 10(12):e038153. PubMed ID: 33268401
[TBL] [Abstract][Full Text] [Related]
14. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.
Kuang Y; Chen Q; Fu Y; Wang Y; Hong Q; Lyu Q; Ai A; Shoham Z
Fertil Steril; 2015 Jul; 104(1):62-70.e3. PubMed ID: 25956370
[TBL] [Abstract][Full Text] [Related]
15. Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation.
Zhu X; Ye H; Fu Y
Fertil Steril; 2017 Sep; 108(3):505-512.e2. PubMed ID: 28697910
[TBL] [Abstract][Full Text] [Related]
16. Luteal-phase ovarian stimulation is a feasible method for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment compared to a GnRH antagonist protocol: A retrospective study.
Wei LH; Ma WH; Tang N; Wei JH
Taiwan J Obstet Gynecol; 2016 Feb; 55(1):50-4. PubMed ID: 26927248
[TBL] [Abstract][Full Text] [Related]
17. Delayed Start Versus Conventional GnRH Antagonist Protocol in Poor Responders Pretreated With Estradiol in Luteal Phase: A Randomized Controlled Trial.
Maged AM; Nada AM; Abohamila F; Hashem AT; Mostafa WA; Elzayat AR
Reprod Sci; 2015 Dec; 22(12):1627-31. PubMed ID: 26045549
[TBL] [Abstract][Full Text] [Related]
18. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
[TBL] [Abstract][Full Text] [Related]
19. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial.
Giles J; Alama P; Gamiz P; Vidal C; Badia P; Pellicer A; Bosch E
Fertil Steril; 2021 Aug; 116(2):404-412. PubMed ID: 33814126
[TBL] [Abstract][Full Text] [Related]
20. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
